Introduction
Nitric oxide (NO ¼ ) is an important intra-and inter-cellular mediator, governing a plethora of physiological functions, from the control of smooth muscle tone in the cardiovascular, gastrointestinal, respiratory and genitourinary systems, to neurotransmission. 1 It is also involved in immune function and inflammation. 2 The role of NO ¼ in tumour biology is complex -it is involved in regulating tumour cell growth and proliferation, it affects transcription of certain genes, and plays a role in host response to tumour growth. 3 NO ¼ production in solid tumours has been implicated in enhanced vascular permeability and increased tumour blood flow; 4 inhibition of NO ¼ synthase (NOS) has been shown to retard tumour growth in vivo. 5 However, the level of NO ¼ appears to be critical in determining the tissue response. When NO ¼ is generated at high concentrations, such as by macrophages, it can cause cell death in tumours. 6 It has also been shown that NO ¼ -donor molecules can inhibit vessel formation in the chick chorioallontoic membrane and reverse the angiogenic effect of alpha thrombin. 7 
NO
¼ has been widely reported as an hypoxic cell radiosensitizer. [8] [9] [10] Using authentic NO ¼ gas, Mitchell et al 8 gen in sensitizing hypoxic Chinese hamster V79 lung cells to radiation, with a sensitizer enhancement ratio (SER) of 2.3 at a concentration of 10 4 p.p.m. In the same study the NO ¼ donor 2,2-diethyl-1-nitroso-oxyhydrazine sodium salt (DEA/NO) gave an SER of 2.9 at a concentration of 2 mm. Very similar results were reported for DEA/NO (SER = 3.0 at 2 mm) and for another NO ¼ donor, spermine/nitric oxide complex (SER = 2.8 at 2 mm) in SCK tumour cells in vitro. 11 Kurimoto et al 10 examined the radiosensitizing effect of the NO ¼ -generating agents S-nitroso-N-acetyl-penicillamine (SNAP) and sodium nitroprusside (SNP) in glioma cells, observing SERs of 1.4 and 1.9 respectively at concentrations of 100 m. Furthermore, a rise in NO ¼ levels as a secondary consequence of IFN-␥ exposure in EMT-6 tumour cells resulted in hypoxic cell radiosensitization. 9 Spontaneous and bioreductive NO ¼ donors, such as SNP and SNAP, elicit systemic vasodilation and hypotension; they cannot therefore be administered in sufficient doses to achieve tumour radiosensitization in the clinic. One strategy for generating NO ¼ specifically within the tumour is the use of iNOS gene therapy. The potential for iNOS in a suicide gene therapy approach has already been effectively demonstrated by several other groups, [12] [13] [14] [15] [16] but we are not aware of any studies in which iNOS gene transfer was combined with radiotherapy.
We have previously demonstrated that transfection of rat arteries with the iNOS gene, under the control of a constitutive CMV promoter, can modify vascular tone by generation of large amounts of NO ¼ . Furthermore, we have shown that we can achieve similar effects by using a radiation inducible promoter, WAF1 17 to drive iNOS expression. 18 There is evidence that the effectiveness of radio and chemotherapy can be compromised by the consequences of inadequate tumour blood flow. 19 Targeted generation of NO ¼ within the tumour volume using a gene therapy approach should therefore enhance these therapies. Effective targeting of the tumour should be achievable using the WAF1 promoter, which is maximally activated within the radiation field by 8 h and this level is maintained for 24 h. 18 This will minimize complications arising from systemic expression of the gene product. This strategy will also exploit the additional anticancer benefits of NO ¼ generation including radiosensitization, cytotoxicity (via interaction with superoxide), anti-angiogenesis 20 and inhibition of tumour metastasis. 13 The aim of this study was to demonstrate the cytotoxic and radiosensitizing potential of iNOS gene transfer in murine RIF-1 tumour cells in vitro and in vivo.
Results

Induction of iNOS protein in RIF-1 cells transiently transfected with CMV/iNOS or WAF1/iNOS
Cells transfected with either the CMV/iNOS or WAF1/iNOS construct were assayed for iNOS protein levels. Cells transfected with the CMV/iNOS construct showed a 2.8-fold increase in iNOS levels over hypoxic non-transfected parental controls and a 5.9-fold increase over oxic non-transfected controls ( Figure 1 ). Those cells transfected with the WAF1/iNOS construct showed iNOS levels 1.8-fold higher than hypoxic non-transfected parental controls and 3.8-fold higher than oxic non-transfected parental controls. Cells treated with only the transfection agent, lipofectamine plus, showed iNOS protein levels 1.2-fold lower than hypoxic non-transfected con- trols, and 2.0-fold higher than oxic non-transfected cells, although these levels were not found to be significantly different (P > 0.05, Kruskal-Wallis test). The levels of nitrite almost mirrored the results for iNOS protein levels except for the lipofectamine control ( Figure 2 ).
Effect of iNOS gene transfer on the radiosensitivity of RIF-1 cells in vitro
Murine RIF-1 tumour cells transiently transfected with CMV/iNOS or WAF1/iNOS were irradiated in air or hypoxia with a range of radiation doses 16 h after a 4 Gy priming dose to induce the WAF1 promoter. Clonogenic cell survival curves for parental controls, lipofectamine alone, CMV/iNOS or WAF1/iNOS transfected cells are shown in Figure 3 . The parental control RIF-1 cells were approximately three times more sensitive in oxic compared with hypoxic conditions (the oxygen enhancement ratio, OER = 2.8). The hypoxic cell survival curves for CMV/iNOS or WAF1/iNOS transfected cells were not significantly different from those of non-transfected parental controls irradiated in air (P > 0.1 for both constructs, Mann-Whitney U test). The OERs were 1.6 for both constructs at the 10% survival level, and 2.6 and 2.4 respectively at the 1% survival level. Cells previously transfected with the WAF1/iNOS construct and exposed to 4 Gy Xrays were also incubated with the NOS inhibitor N G -monomethyl-l-arginine (L-NMMA; Sigma Chemical, Poole, UK) for 1 h before irradiation. This treatment eliminated the radiosensitizing effect of iNOS transfection. Table 1 lists the percentage survival of cells transfected, but not given a treatment dose of radiation; statistically significant cytotoxicity (P Ͻ 0.05, ANOVA) was observed only in cells transfected with CMV/iNOS (~30% cell kill).
Radiosensitization of RIF-1 tumours in vivo by iNOS gene transfer
Intradermal RIF-1 tumours were injected with the CMV/iNOS/liposome complex and irradiated 24 h later with 10 or 20 Gy X-rays. Tumour growth curves are shown in Figure 4 . Treatment effectiveness was evaluated by calculating the time to reach four times treatment volume. In the control group that received no treatment, tumours reached four times treatment volume after 5.6 days. The growth delay achieved by each treatment is 
Figure 3 Radiation cell survival curves for RIF-1 tumour cells transfected with CMV/iNOS or WAF1/iNOS. Cells were exposed to a range of radiation doses 16 h after an initial 4 Gy priming dose to activate the WAF1 promoter. All cells were irradiated under hypoxia with the exception of the oxic control. Each point is the mean of three separate experiments ± s.e. Surviving fraction was calculated after correction for plating efficiency of non-irradiated cells for each treatment condition, hence all curves originate from a surviving fraction of 1.
Table 1
Cytotoxicity of iNOS gene transfer in RIF-1 tumour cells (with 4 Gy priming dose only)
Plating efficiency (%)
Surviving faction (% of lipofectamine control) Table 2 . Treatment with 20 Gy X-rays alone, or injection of empty pcDNA3.1 vector followed by 20 Gy X-rays was similarly effective delaying tumour regrowth by a further 2.9 and 3.1 days, respectively. Tumours injected with the CMV/iNOS construct, but receiving no radiation had a tumour growth delay of 4.2 days compared with controls, while injection of the iNOS construct and exposure to 10 Gy or 20 Gy resulted in significant growth delays of 8.4 days and 19.7 days compared with controls (P Ͻ 0.05, two-tailed unpaired t test).
Levels of iNOS protein in tumours injected with the iNOS construct
Protein levels were measured in tumours injected with the iNOS construct and compared with non-injected control tumours. Figure 5 shows densitometric analysis of western blots detecting iNOS protein levels. Twenty-four Gene Therapy hours after injection, tumours which received the iNOS construct showed iNOS protein expression 2.44-fold higher than those tumours which were not injected.
Histological examination of CMV/iNOS injected tumours
RIF-1 tumours showed extensive regions of necrosis (extending to >1 mm 2 ) 5 days after a single injection of CMV/iNOS construct (Figure 6a ). Control tumours showed few necrotic areas and these were not extensive (Figure 6b ). There were also many cells with the characteristic appearance of apoptotic cell death. Serial sections stained using the TUNEL method identified large numbers of apoptotic cells in CMV/iNOS injected tumours (Figure 6c ). Non-transfected control tumours showed very few TUNEL stained cells (Figure 6d ).
Discussion
The role of nitric oxide in cancer is complex, reflecting its role as a mediator in numerous physiological pathways. [3] [4] [5] [6] [7] The data presented here indicate clearly that, under the experimental conditions used, NO ¼ was both cytotoxic to, and a radiosensitizer of, various populations of cells within the tumour, as revealed histologically (by necrosis and apoptosis) and by growth delay. These observations are in apparent contrast to previous reports demonstrating that tumours in mice and rats are highly dependent on NO ¼ for the maintenance of a high growth rate and that inhibition of NOS in vivo reduces the growth rate of tumours, 5 probably by reducing their blood flow. 21 There must, therefore, be an optimum NO ¼ level that is sufficient to keep the tumour vasculature in a fully dilated condition, but which is below the level at which cytotoxocity will occur. This balance between vasodilatory and cytotoxic effects is likely to be very variable as sensitivity to the cytotoxic/antiproliferative effects of NO ¼ have been shown to differ by a factor of 10 between tumour cell lines. 11 The mechanisms responsible for cell death resulting from NO ¼ production are complex, but involve the formation of peroxynitrite, 22 nitrosating agents such as N 2 O 3 23 or nitroxyl; 24 the concentrations required are probably in the 3-10 mm range as shown for the production of DNA single strand breaks. 22 In the present study the cytotoxic effects of NO ¼ were evident in both the in vitro and in vivo systems. In vitro 30% of the cells were killed by prolonged expression of iNOS in the CMV/iNOS group (Table 1) . This percentage is approximately equal to the transfection efficiency in these cells (data not shown) so it seems reasonable to conclude that most of the transfected cells are killed by the high intracellular NO ¼ concentrations generated over several days. Cytotoxicity was minimal in cells transfected with the WAF1/iNOS construct yet they were radiosensitized by the generated NO ¼ . This may be because the duration of iNOS expression (and hence NO ¼ generation) induced by the 4 Gy priming dose of radiation 18 was suf-
Figure 6 Photomicrographs of RIF-1 tumours 5 days after transfection with the CMV/iNOS construct. (A) Haematoxylin and eosin staining of CMV/iNOS injected tumour section showing areas of necrosis (original magnification ×40). (B) Haematoxylin and eosin staining of control, nontransfected tumour section (original magnification ×40). (C) Abundant apoptotic nuclei in CMV/iNOS transfected tumour section. Apoptotic nuclei were stained using a fluorescent detection method for DNA strand breaks (TUNEL method, Mebstain II) (original magnification ×40). (D) Few apoptotic nuclei in control, non-transfected tumour tissue (original magnification ×40).
ficient to cause radiosensitization 24 h later but did not persist long enough to cause substantial cell killing. Cytotoxicity in vivo was much more dramatic than that seen in vitro. The group of tumours receiving CMV/iNOS transfection in the absence of radiation had a growth delay equal to that resulting from a radiation dose of 20 Gy alone. The level of cell kill required to achieve this effect cannot be calculated precisely, but based on the in vitro cell survival curves (Figure 3 ) it must be greater than 98%. In addition to the directly cytotoxic effect of the interaction of NO ¼ with superoxide, 25 it should also be born in mind that NO ¼ production at high levels in vivo is likely to be anti-angiogenic. 26 There is also evidence that the cytotoxic effect of NO ¼ is mediated through its reaction with O 2 Ϫ to form the apoptosis inducer peroxynitrite. 27 In addition, the number of activated macrophages expressing endogenous iNOS will probably be increased as a response to the gene therapy treatment. Induction of the immune response has previously been described following various other suicide gene therapy protocols. [28] [29] [30] Furthermore, the cytotoxicity of macrophages migrating within the tumour taking up the CMV/iNOS would probably enhance tumour cell kill. 31 Radiosensitization by NO ¼ was also observed in vitro and in vivo in the present study (Figures 3 and 4) . Sensitization in vitro was highly efficient regardless of whether iNOS was expressed constitutively (CMV/iNOS group, SER = 2.8) or produced by radiation induction (WAF1/iNOS, SER = 2.4); in each case it is clear that at least 99% of the cells were sensitized (Figure 3) . Bearing in mind the transfection efficiency of approximately 30% (data not shown) this implies a very efficient 'bystander' effect, which is consistent with that previously observed in bystander murine cells co-cultured with melanoma cells expressing an iNOS transgene. An unexpected feature of the in vitro survival data (Figure 3 ) is that the survival curves for the hypoxic control, lipofectamine control and WAF/iNOS + L-NMMA are not of the expected log/linear shape, suggesting the existence of more than one population of cells with differing radiosensitivities. One likely explanation is that the 1 h nitrogen gassing procedure alone did not succeed in eliminating all the oxygen from the flasks, resulting in an oxygen enhancement ratio of only about 2.0 for flasks with low cell density. In the higher radiation dose groups, where much higher cell densities were plated, cellular metabolism would have removed the last traces of oxygen, so revealing the true oxygen enhancement ratio of about 2.6. The effect of this would be to reduce the apparent effectiveness of iNOS gene transfer at low doses.
These data exemplify why NO ¼ is such a potentially useful molecule for cancer gene therapy. The level of radiosensitization (SER) resulting from iNOS transfection in the present study was similar to that reported by Mitchell et al 8 who found an SER of 2.4 using 4 × 10 4 p.p.m. authentic NO ¼ gas. The observation ( Figure 3 ) that both cytotoxicity and radiosensitization in vitro can be entirely abrogated by L-NMMA, a known inhibitor of NOS, 33 clearly demonstrates that the radiosensitization is mediated by a product of iNOS. We cannot state categorically, however, that NO ¼ is the only active species. Other reactive nitrogen oxides such as peroxnitrite, N 2 O 3 and nitroxyl may also play a role. 26 RIF-1 tumour cells appear to have high levels of endogenous iNOS protein. However, this may be explained by the fact that all groups were exposed to a 4 Gy priming dose 24 h before measurement of iNOS protein levels; it has been reported that radiation could augment production of NO ¼ . 34 Nevertheless, transfection with CMV/iNOS or WAF1/iNOS significantly enhanced iNOS protein levels compared with lipofectamine alone control. NO ¼ -releasing agents have been used to sensitize hypoxic cells to radiation, but the results are inconsistent. Douple et al 35 observed that sodium nitroprusside (SNP) radiosensitized both aerobic and hypoxic Chinese hamster V79 cells, although Mitchell et al 8 reported no effect of SNP in that same cell line exposed to hypoxia. In contrast, Verovski et al 36 found that SNP radiosensitized hypoxic pancreatic tumour cells, and that this radiosensitization by SNP was only observed under hypoxic conditions.
In this study we have effectively demonstrated that delivery of iNOS to tumour cells both in vitro and in vivo can generate sufficient NO ¼ to cause cytotoxicity and radiosensitization of hypoxic cells. Hypoxic cells are a feature of tumours (the RIF-1 tumour in our laboratory has a hypoxic fraction of approximately 5%) that are known to limit the success of conventional treatments and have recently been implicated in the promotion of malignant progression and metastasis. 37 Therefore, the ability to eliminate hypoxic cells is of fundamental importance to the treatment of cancer.
The in vivo experimental protocol used in this study was aimed at establishing the principle of combining iNOS and radiation, but was not optimized for maximal efficacy. While the effects on tumour growth were dramatic, it is likely that by optimizing the treatment protocol (eg multiple iNOS injection sites, repeated iNOS injecGene Therapy tions combined with fractionated irradiation) even more impressive responses should be achievable.
There have been few studies investigating the use of iNOS in cancer gene therapy, 12, 15, 16 only one of which describes specific targeting of this gene to tumour cells. 38 Our strategy for targeting iNOS to tumour cells uses radiation both to activate the radiation-inducible promoter, WAF1, and to interact with the gene product NO ¼ to target hypoxic tumour cells. This combination is extremely effective in vitro and further studies in vivo will inform the design of a clinically appropriate protocol.
Materials and methods
Maintenance of RIF-1 cells in vitro and in vivo
Murine fibrosarcoma cells (RIF-1) were kindly provided by Prof M Brown, Stanford University, Stanford, CA, USA) and were routinely maintained according to the established protocol of Twentyman et al. 39 Cells were grown as monolayers in RPMI 1640 medium (Gibco BRL, Paisley, UK) supplemented with fetal calf serum (15%) (Globepharm, UK), at 37°C under 5% CO 2 /95% air and passaged every 3-4 days to maintain exponential growth.
Tumours for in vivo experiments were obtained by intradermal injection of 2 × 10 5 cells (in a volume of 0.1 ml of medium) on the rear dorsum of lightly anaethetized (isofluorane inhalation) 10-to 12-week-old female C3H mice. Mice were treated when tumours reached a volume of 150-250 mm 3 . All animal experiments were carried out in accordance with the Animals (Scientific Procedures) Act 1986 and conformed to the current UKCCCR guidelines.
CMV/iNOS vector
The iNOS cDNA was a kind gift from Dr T Billiar (School of Medicine, Pittsburgh, PA, USA). iNOS was excised from the original construct and directionally cloned into the Kpnl-Notl restriction sites of the mammalian expression vector, pcDNA 3.1 (Invitrogen, Groningen, The Netherlands).
WAF1/iNOS vector
The WAF1 promoter was provided by Prof B Vogelstein (John Hopkins Oncology Centre, Baltimore, MD, USA). It was then excised from the original construct, blunt ended using Klenow (Life Technologies, UK) and ligated into the blunt-ended pcDNA3.1/iNOS vector after removal of the CMV promoter using Nhel and Nrul.
In vitro transfections RIF-1 cells (1 × 10 6 ) were seeded into 25 ml tissue culture flasks and incubated overnight at 37°C, 95% air/5% CO 2 . The cells were transfected for 4 h with 10 g of the CMV/iNOS or WAF1/iNOS construct using Lipofectamine Plus (Life Technologies, UK), according to the manufacturer's instructions.
Determination of cell kill following treatment with X-rays in iNOS-transfected and control RIF-1 cells using an in vitro clonogenic assay
Four hours following transfection the medium containing the DNA/liposome complexes was replaced with normal growth medium (supplemented with 1 × 10 -5 m tetrahydrobiopterin (BH 4 ; Sigma, Poole, UK), a known co-factor of iNOS. Previous studies in our laboratory 18 have shown that BH 4 supplementation is necessary for maximal, NO ¼ -induced dilation of rat-tail artery segments following iNOS gene transfer. All groups were then given a 4 Gy priming dose of X-rays. This was specifically to induce gene expression via WAF1, but it was necessary to irradiate all groups in this way to allow for the cytotoxicity of this X-ray dose.
Sixteen hours later, non-transfected parental control cells were incubated for 1 h in oxic (95% air/5% CO 2 ) conditions before irradiation. All other cell groups (nontransfected parental controls, lipofectamine-treated cells, CMV/iNOS transfected cells, WAF1/iNOS transfected cells and WAF1/iNOS transfected cells + L-NMMA; Sigma) were incubated in hypoxic (95%N 2 /5% CO 2 ) conditions for the same period. Cells were then irradiated at room temperature under air or hypoxia (as above) at doses of 3, 6, 9, 12, 18, 24 and 30 Gy using a Therapax X-ray machine (Pantak, Reading, UK) operated at 90 kV (dose rate: 1.17 Gy/min). After irradiation the cells were trypsinized and seeded into six-well plates in triplicate, at cell numbers appropriate to the expected level of survival. The plates were then incubated under normal conditions (95% air/5% CO 2 at 37°C) for 14 days, after which the colonies were fixed in 70% methanol, stained with crystal violet (0.4%) and counted. Three independent experiments were performed. Cell survival curves were constructed after correction for plating efficiency of cells treated in the same way in the absence of radiation. Sensitizer enhancement ratios (SER) were calculated by dividing the radiation dose for control hypoxic conditions by the radiation dose for transfected cells under hypoxic conditions required to give a surviving fraction of 1%.
In vivo tumour growth delay assay
When RIF-1 tumours reached the appropriate treatment size (150-250 mm 3 ), animals were allocated randomly to treatment groups -controls: no treatment (n = 6), 20 Gy X-rays (n = 6), empty pcDNA3.1 + vector plus 20 Gy (n = 6); treatment groups: CMV/iNOS alone (n = 9), CMV/iNOS plus 10 Gy (n = 9), CMV/iNOS plus 20 Gy (n = 9).
Transfection of tumour cells in vivo was carried out by direct injection of 25 g of CMV/iNOS 24 h before irradiation, using a TransIT in vivo transfection kit (Mirus, USA). These mice were also injected i.p. with 20 l of 10 -3 m BH 4 . On the day of irradiation mice were placed in lead jigs to shield the entire body of the animal with the exception of the tumour. The tumours were then irradiated in air with doses of 10 or 20 Gy X-rays (0.85 Gy/min) using a Pantak 250 kV X-ray machine. Tumours were measured every day until day 5, then every 2 days until the tumour reached four times its treatment size. The animal was then killed. Growth curves were plotted for each group.
Western blotting
In vitro samples for protein analysis were extracted by lysing cells with Laemmli buffer (Sigma). For tumour tissue samples the animal was killed 24 h after injection of the tumour with the CMV/iNOS construct. The tumour was removed and protein extracted using Trizol reagent (Life Technologies, Paisley, UK) according to the manufacturer's instructions. Protein concentration was measured using the BioRad Protein Assay (BioRad, Munich, Germany). Thirty g of each sample was electrophoresed through a 1% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane (Hybond C; Amersham, UK) and probed with a mouse monoclonal anti-iNOS antibody (Transduction Laboratories, Lexington, KY, USA). Levels of gene expression were assessed using an ECL detection kit with Hoefer Analysis software (Hoefer, San Francisco, CA, USA) to assess the intensity of each band on the autoradiograph. Three independent experiments were carried out and the mean results reported ± s.e.
Measurement of nitrite levels NO
¼ generated as a result of iNOS expression, is rapidly oxidized to nitrite (NO 2 -) and nitrate (NO 3 -); NO ¼ generation was, therefore, determined by measurement of nitrite in the cell culture medium. Equal volumes of cell culture medium and Greiss reagent 40 (Sigma) were mixed, incubated at room temperature for 15 min, then absorbance at 570 nm determined. Fresh tissue culture medium served as the blank and solutions of NaNO 2 in culture medium served as standards.
Tumour histology and apoptosis detection in vivo in RIF-1 tumours
Tumours were excised at various times (1, 2, 3, 5, 7 and 10 days) following injection of the CMV/iNOS construct. The tumour was then fixed in paraformaldehyde (Sigma) (4%) embedded in paraplast embedding medium (Sigma) and sectioned. Serial sections were stained with haematoxylin and eosin and apoptotic cells were detected using the Mebstain Apoptosis Kit II (MBL, Japan) according to the manufacturer's instructions. Labelled nuclei were identified by fluorescence microscopy (Olympus BX50F-3, Japan).
